Key Highlights

  • Coherus BioSciences finalized a $55 million senior secured term Loan with an August 2031 maturity.
  • The loan refinances higher-cost Debt previously due in May 2029.
  • The move provides $45 million in potential future funding while adding new financial covenants.
  • The company set a September 30, 2026 Record Date for a special CVR Dividend tied to its biosimilar assets.

Coherus BioSciences, Inc. (NASDAQ: CHRS) finalized a $55 million senior secured term loan with an August 2031 Maturity to refinance higher-cost debt previously due in May 2029.

What Happened

The move secures immediate Liquidity and provides $45 million in potential future funding while adding new financial covenants.

The company also set a September 30, 2026 record date for a special CVR dividend, allowing investors to share in potential proceeds from monetizing biosimilar Assets through 2028 as Coherus pivots its primary focus toward its immuno-oncology pipeline.

Market Reaction

The disclosed information does not include stock price or trading data for Coherus BioSciences following the refinancing and CVR dividend announcements.

Outlook

The September 30, 2026 record date for the special CVR dividend, along with continued monetization of biosimilar assets through 2028, represent the next disclosed milestones as the company shifts its strategic focus toward immuno-oncology.